Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
Funding Amount
Up to $350,000
Deadline
December 23, 2027
445 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Special district governments
- Public & Indian housing authorities
- County governments
- City & township governments
- Tribal organizations
- Public colleges & universities
- For-profit businesses
- State governments
Geography
- Non-domestic (non-U.S.) components of U.S.
Other requirements
- Organizations are eligible to apply.
- Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Not eligible / not funded
- Not eligible: Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Overview
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-HL-26-016
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Focus Areas & Funding Uses
Fields of Work
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health
Amount
Varies
Deadline
October 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health
Amount
Up to $1M
Deadline
October 9, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 9, 2026
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$650,000 total
Deadline
October 9, 2026
Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)
National Institutes of Health
Amount
$5,000,000 total
Deadline
October 11, 2026
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
October 14, 2026
Ready to apply for Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed). Now let's win it.